Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACB 
Aurora Cannabis Inc (ACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: ACB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.24
1 Year Target Price $6.24
| 3 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.53% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 298.14M USD | Price to earnings Ratio - | 1Y Target Price 6.24 |
Price to earnings Ratio - | 1Y Target Price 6.24 | ||
Volume (30-day avg) 6 | Beta 3.26 | 52 Weeks Range 3.42 - 6.91 | Updated Date 10/12/2025 |
52 Weeks Range 3.42 - 6.91 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.05% | Operating Margin (TTM) -20.63% |
Management Effectiveness
Return on Assets (TTM) -0.81% | Return on Equity (TTM) -1.19% |
Valuation
Trailing PE - | Forward PE 13.4 | Enterprise Value 292345617 | Price to Sales(TTM) 0.83 |
Enterprise Value 292345617 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 1.14 | Enterprise Value to EBITDA 15.32 | Shares Outstanding 56252660 | Shares Floating 56154742 |
Shares Outstanding 56252660 | Shares Floating 56154742 | ||
Percent Insiders - | Percent Institutions 14.79 |
Upturn AI SWOT
Aurora Cannabis Inc
Company Overview
History and Background
Aurora Cannabis Inc. was founded in 2006 and is headquartered in Edmonton, Canada. It has grown through acquisitions and organic expansion to become a significant player in the global cannabis market.
Core Business Areas
- Cannabis Production and Sales: Cultivation, processing, and sale of dried flower, oils, capsules, and other cannabis products for medical and recreational markets.
- Medical Cannabis: Focus on research, development, and distribution of medical cannabis products for patients with specific health conditions.
- International Expansion: Developing operations and partnerships in international markets, including Europe and Australia.
Leadership and Structure
Miguel Martin serves as the Chief Executive Officer. The company operates with a board of directors and various executive teams overseeing different business segments.
Top Products and Market Share
Key Offerings
- Dried Flower: Various strains of dried cannabis flower for recreational and medical use. Competitors include Canopy Growth, Tilray, and Curaleaf. Revenue from dried flower sales accounts for a significant portion of overall cannabis revenue.
- Cannabis Oils and Extracts: Cannabis oils and extracts for consumption and topical application. Competitors include Canopy Growth, Cronos Group, and Organigram. This sector of cannabis revenue makes up an increasing fraction of overall cannabis revenue with ongoing product development.
- Edibles: Cannabis edibles, providing alternative ways of administering cannabis. Competitors include Wana Brands, and Curaleaf. Market share is generally small.
Market Dynamics
Industry Overview
The cannabis industry is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is highly competitive, with numerous players vying for market share.
Positioning
Aurora Cannabis Inc. aims to be a leading global cannabis company. Its competitive advantages include its production capacity, research and development capabilities, and international presence.
Total Addressable Market (TAM)
The global cannabis market is expected to reach hundreds of billions of USD in the coming years. Aurora Cannabis Inc. is positioned to capture a portion of this market through its global expansion efforts.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Significant production capacity
- Strong medical cannabis focus
- International presence
Weaknesses
- Inconsistent profitability
- High operating expenses
- Significant debt load
- Dilution of share value
Opportunities
- Expansion into new international markets
- Development of innovative cannabis products
- Partnerships and collaborations with other companies
- Increased legalization and acceptance of cannabis
Threats
- Intense competition
- Regulatory uncertainty
- Price volatility
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- CGC
- TLRY
- CRON
- GTBIF
Competitive Landscape
Aurora Cannabis Inc. faces intense competition from other large cannabis companies. The company's ability to differentiate its products and control costs will be key to its success.
Major Acquisitions
MedReleaf Corp.
- Year: 2018
- Acquisition Price (USD millions): 2640
- Strategic Rationale: Expanded production capacity and strengthened market position.
Growth Trajectory and Initiatives
Historical Growth: Aurora Cannabis Inc. has experienced rapid revenue growth in the past, but also significant losses.
Future Projections: Future projections for Aurora Cannabis Inc. are subject to various factors, including regulatory changes and competitive dynamics.
Recent Initiatives: Recent initiatives include cost-cutting measures, debt restructuring, and a focus on profitability.
Summary
Aurora Cannabis faces strong headwinds with respect to profitability and debt management. While its international footprint and medical cannabis focus are strengths, intense competition and regulatory uncertainty pose significant challenges. The company needs to demonstrate consistent profitability and manage its debt effectively to achieve long-term success. Continued cost-cutting and focusing on profitable segments will be critical to its survival and growth. They must also look out for regulatory changes which may affect their profit margin.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurora Cannabis Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 2014-07-11 | CEO & Executive Chairman Mr. Miguel Martin | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.auroramj.com |
Full time employees - | Website https://www.auroramj.com | ||
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants. It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.